Dashboard
Manage Tickers

RGNXREGENXBIO Inc.

Nasdaq regenxbio.com


$ 16.66 $ -0.29 (-1.71 %)    

Wednesday, 08-May-2024 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 16.67
$ 17.29
$ 0.00 x 0
$ 0.00 x 0
$ 16.24 - $ 17.29
$ 11.83 - $ 28.80
326,222
na
729.05M
$ 1.42
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-08-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-08-2023 09-30-2023 10-Q
4 08-02-2023 06-30-2023 10-Q
5 05-03-2023 03-31-2023 10-Q
6 02-28-2023 12-31-2022 10-K
7 11-03-2022 09-30-2022 10-Q
8 08-03-2022 06-30-2022 10-Q
9 05-04-2022 03-31-2022 10-Q
10 03-01-2022 12-31-2021 10-K
11 11-02-2021 09-30-2021 10-Q
12 08-09-2021 06-30-2021 10-Q
13 05-05-2021 03-31-2021 10-Q
14 03-01-2021 12-31-2020 10-K
15 11-04-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-07-2020 03-31-2020 10-Q
18 02-26-2020 12-31-2019 10-K
19 11-05-2019 09-30-2019 10-Q
20 08-07-2019 06-30-2019 10-Q
21 05-07-2019 03-31-2019 10-Q
22 02-27-2019 12-31-2018 10-K
23 11-07-2018 09-30-2018 10-Q
24 08-08-2018 06-30-2018 10-Q
25 05-08-2018 03-31-2018 10-Q
26 03-06-2018 12-31-2017 10-K
27 11-08-2017 09-30-2017 10-Q
28 08-08-2017 06-30-2017 10-Q
29 05-09-2017 03-31-2017 10-Q
30 03-07-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-09-2016 06-30-2016 10-Q
33 05-05-2016 03-31-2016 10-Q
34 03-03-2016 12-31-2015 10-K
35 11-05-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

regenxbio-q1-2024-gaap-eps-138-misses-123-estimate-sales-15622m-miss-23525m-estimate
Regenxbio Q1 2024 GAAP EPS $(1.38) Misses ...
05/08/2024 21:37:56

Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(1.23) b...

where-regenxbio-stands-with-analysts
Where Regenxbio Stands With Analysts
04/12/2024 16:01:22

stifel-maintains-buy-on-regenxbio-maintains-40-price-target
Stifel Maintains Buy on Regenxbio, Maintai...
04/12/2024 15:53:51

Stifel analyst Annabel Samimy maintains Regenxbio (NASDAQ:RGNX) with a Buy and maintains $40 price target.

Core News & Articles
REGENXBIO Announces Lancet Publication of ...
03/28/2024 11:09:41

REGENXBIO Inc. (NASDAQ:RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and to...

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
03/25/2024 21:32:19

hc-wainwright--co-initiates-coverage-on-regenxbio-with-buy-rating-announces-price-target-of-36
HC Wainwright & Co. Initiates Coverage On ...
03/11/2024 13:39:24

HC Wainwright & Co. analyst Yi Chen initiates coverage on Regenxbio (NASDAQ:RGNX) with a Buy rating and announces Price ...

this-gene-therapy-player-duchenne-data-is-impressive-analyst-upgrades-regenxbio
This Gene Therapy Player Duchenne Data Is ...
03/08/2024 18:43:05

REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 t...

regenxbio-shares-are-trading-higher-after-rbc-capital-upgraded-the-stock-from-sector-perform-to-outperform-and-raised-its-price-target-from-20-to-35
Regenxbio shares are trading higher after ...
03/08/2024 13:48:00

rbc-capital-upgrades-regenxbio-to-outperform-raises-price-target-to-35
RBC Capital Upgrades Regenxbio to Outperfo...
03/08/2024 12:59:17

RBC Capital analyst Luca Issi upgrades Regenxbio (NASDAQ:RGNX) from Sector Perform to Outperform and raises the price target...

chardan-capital-maintains-buy-on-regenxbio-maintains-52-price-target
Chardan Capital Maintains Buy on Regenxbio...
03/07/2024 14:45:05

Chardan Capital analyst Daniil Gataulin maintains Regenxbio (NASDAQ:RGNX) with a Buy and maintains $52 price target.

barclays-maintains-overweight-on-regenxbio-raises-price-target-to-55
Barclays Maintains Overweight on Regenxbio...
03/07/2024 12:16:56

Barclays analyst Gena Wang maintains Regenxbio (NASDAQ:RGNX) with a Overweight and raises the price target from $45 to $55.

regenxbio-prices-upsized-public-offering-of-4565260-common-shares-at-23share-and-1521740-pre-funded-warrants-at-229999warrant
REGENXBIO Prices Upsized Public Offering O...
03/07/2024 07:44:07

 The gross proceeds to REGENXBIO from the offering, before deducting the underwriting discounts and commissions and other offer...

regenxbio-announces-proposed-125m-public-offering-of-common-stock
REGENXBIO Announces Proposed $125M Public ...
03/06/2024 21:30:42

REGENXBIO Inc. (NASDAQ:RGNX) today announced that it intends to offer and sell, subject to market conditions, $125,000,000 of i...

leerink-partners-upgrades-regenxbio-to-outperform
Leerink Partners Upgrades Regenxbio to Out...
03/06/2024 14:33:01

Leerink Partners analyst Mani Foroohar upgrades Regenxbio (NASDAQ:RGNX) from Market Perform to Outperform.

beyond-the-numbers-4-analysts-discuss-regenxbio-stock
Beyond The Numbers: 4 Analysts Discuss Reg...
03/06/2024 13:00:56

baird-maintains-outperform-on-regenxbio-raises-price-target-to-39
Baird Maintains Outperform on Regenxbio, R...
03/06/2024 12:55:28

Baird analyst Brian Skorney maintains Regenxbio (NASDAQ:RGNX) with a Outperform and raises the price target from $34 to $39.

regenxbios-muscle-wasting-disorder-drug-shows-strength-improved-motor-function-stock-soars
REGENXBIO's Muscle Wasting Disorder Drug S...
03/05/2024 17:07:51

Latest updates on safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE trial for Duchenne muscular dystrophy. Positive result...

12-health-care-stocks-moving-in-tuesdays-pre-market-session
12 Health Care Stocks Moving In Tuesday's ...
03/05/2024 13:09:49

regenxbio-announces-new-initial-efficacy-data-from-affinity-duchenne-trial
Regenxbio Announces New Initial Efficacy D...
03/05/2024 12:07:30

REGENXBIO Inc. (NASDAQ:RGNX) today reported additional interim safety and efficacy data in the Phase I/II AFFINITY DUCHENNE® tr...

why-zscaler-shares-are-trading-lower-by-10-here-are-other-stocks-moving-in-fridays-mid-day-session
Why Zscaler Shares Are Trading Lower By 10...
03/01/2024 18:19:25

Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION